Emiliano Calvo Selected Research

SR 271425

2/2009

A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emiliano Calvo Research Topics

Disease

64	Neoplasms (Cancer) 01/2022 - 09/2002
13	Renal Cell Carcinoma (Grawitz Tumor) 04/2022 - 03/2009
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2022 - 01/2003
10	Disease Progression 02/2022 - 06/2013
7	Fatigue 01/2022 - 01/2016
7	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2021 - 07/2016
6	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2002
6	Nausea 01/2022 - 01/2016
5	Neutropenia 01/2021 - 04/2008
5	Carcinoma (Carcinomatosis) 11/2019 - 11/2016
4	Exanthema (Rash) 01/2021 - 05/2009
3	Squamous Cell Carcinoma of Head and Neck 02/2022 - 01/2021
3	Melanoma (Melanoma, Malignant) 01/2022 - 08/2014
3	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2002
3	Vomiting 01/2021 - 11/2016
3	Neoplasm Metastasis (Metastasis) 03/2015 - 03/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2017
2	Triple Negative Breast Neoplasms 01/2021 - 08/2014
2	Headache (Headaches) 01/2021 - 05/2009
2	Hypertension (High Blood Pressure) 10/2020 - 05/2009
2	Adenocarcinoma 10/2020 - 01/2019
2	Lung Neoplasms (Lung Cancer) 01/2018 - 12/2004
2	Febrile Neutropenia 01/2017 - 03/2015
2	Thrombocytopenia (Thrombopenia) 01/2017 - 08/2014
2	Pneumonia (Pneumonitis) 07/2016 - 08/2010
2	Anemia 06/2015 - 03/2015
2	Glioma (Gliomas) 04/2015 - 02/2015
2	Stomatitis 03/2015 - 04/2008
2	Hyperglycemia 10/2011 - 04/2008
1	Microsatellite Instability 01/2022

Drug/Important Bio-Agent (IBA)

9	NivolumabIBA 01/2020 - 07/2016
7	LigandsIBA 02/2022 - 03/2005
7	Phosphotransferases (Kinase)IBA 01/2021 - 02/2009
7	Everolimus FDA Link 11/2020 - 04/2008
7	Gemcitabine FDA Link 12/2018 - 01/2003
6	Pharmaceutical PreparationsIBA 01/2022 - 04/2010
6	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2003
6	Proteins (Proteins, Gene)FDA Link 10/2020 - 12/2004
6	IpilimumabIBA 01/2020 - 07/2016
5	Immune Checkpoint InhibitorsIBA 04/2022 - 01/2018
5	Monoclonal AntibodiesIBA 01/2022 - 03/2005
5	PlatinumIBA 01/2021 - 07/2016
5	TOR Serine-Threonine KinasesIBA 11/2020 - 04/2008
5	Sunitinib (Sutent)FDA Link 11/2020 - 10/2008
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2015
4	Dihydrotachysterol (AT 10)IBA 01/2019 - 04/2008
4	LY2603618IBA 01/2017 - 10/2014
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 06/2015
3	PM 01183IBA 11/2021 - 01/2017
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 12/2004
3	B7-H1 AntigenIBA 01/2021 - 10/2018
3	LY-2157299IBA 01/2021 - 02/2015
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2020 - 02/2009
3	pembrolizumabIBA 10/2020 - 12/2018
3	RamucirumabIBA 10/2020 - 12/2018
3	Cetuximab (Erbitux)FDA Link 09/2019 - 03/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 05/2009
3	Docetaxel (Taxotere)FDA Link 03/2015 - 11/2002
3	Tyrosine Kinase InhibitorsIBA 05/2014 - 09/2002
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 05/2013 - 05/2006
3	Sorafenib (BAY 43-9006)FDA Link 07/2012 - 02/2009
3	Imatinib Mesylate (Gleevec)FDA Link 02/2009 - 09/2002
3	ErbB Receptors (EGF Receptor)IBA 05/2006 - 12/2004
3	Vinorelbine (Navelbine)FDA LinkGeneric 06/2004 - 11/2002
2	budigalimabIBA 02/2022 - 01/2021
2	AntigensIBA 01/2022 - 01/2021
2	AntibodiesIBA 01/2022 - 03/2015
2	Alanine Transaminase (SGPT)IBA 01/2022 - 06/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2021 - 10/2021
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 10/2020
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2021 - 04/2015
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 10/2015
2	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 02/2009
2	erdafitinibIBA 01/2019 - 10/2015
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 08/2014
2	Checkpoint Kinase 1IBA 01/2017 - 01/2017
2	Pemetrexed (MTA)FDA Link 01/2017 - 10/2014
2	Axitinib (AG 013736)IBA 10/2015 - 05/2014
2	Transforming Growth Factors (Transforming Growth Factor)IBA 04/2015 - 02/2015
2	Bevacizumab (Avastin)FDA Link 08/2014 - 05/2009
2	Paclitaxel (Taxol)FDA LinkGeneric 08/2014 - 01/2003
2	temsirolimus FDA Link 03/2013 - 02/2009
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2002 - 01/2002
2	Irinotecan (Camptosar)FDA LinkGeneric 08/2002 - 01/2002
2	Fluorouracil (Carac)FDA LinkGeneric 08/2002 - 01/2002
1	Death Domain ReceptorsIBA 01/2022
1	cyclopropapyrroloindoleIBA 01/2022
1	CytokinesIBA 01/2022
1	triplex DNA (H-DNA)IBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022
1	tebentafuspIBA 11/2021
1	Glycoproteins (Glycoprotein)IBA 11/2021
1	Peptides (Polypeptides)IBA 11/2021

Therapy/Procedure

31	Therapeutics 01/2022 - 01/2003
9	Drug Therapy (Chemotherapy) 01/2020 - 11/2002
4	Immunotherapy 01/2022 - 01/2020
3	Radiotherapy 01/2021 - 03/2009
2	TP protocol 06/2004 - 01/2003
2	Combination Drug Therapy (Combination Chemotherapy) 06/2004 - 08/2002
1	Duration of Therapy 02/2022